Drug intelligence / Profile preview

MVA-MERS-S

Development stage: Phase 1
Lead developer: German Center for Infection Research
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

MVA-MERS-S is a vaccine candidate developed to protect against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). It uses a modified vaccinia virus Ankara (MVA) as a vector, expressing the full-length spike glycoprotein of MERS-CoV. This recombinant vaccine aims to induce immunity against MERS-CoV by stimulating both humoral and cell-mediated immune responses. It has shown a favorable safety profile in clinical trials and is being further developed for potential use in high-risk populations.

Other names: MERSCoV vaccine IDT Biologika GmbH/LudwigMaximiliansUniversityMiddle East respiratory syndrome coronavirus vaccine IDT Biologika GmbH/LudwigMaximiliansUniversity

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on MVA-MERS-S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVA-MERS-S.

Explore the full profile